Read More

eFFECTOR Therapeutics To Collaborate With The Northwestern University Division Of Hematology And Oncology On An Investigator-Initiated Phase 1 Dose Escalation Trial Evaluating Tomivosertib In Patients With Acute Myeloid Leukemia

eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced the initiation of dosing in an

EFTR